Chr Hansen to acquire Jennewein Biotechnologie for $365m.

Chr Hansen, a bioscience company, agreed to acquire Jennewein Biotechnologie, an international industrial biotechnology company, for $365m. “This partnership will further strengthen the position of Jennewein Biotechnologie in this highly attractive growth market. Chr. Hansen and Jennewein Biotechnologie are a perfect fit with regards to culture, production technology, as well as product portfolio," Stefan Jennewein and Klaus Jennewein, Jennewein Biotechnologie Founder and CEO.